The state corporation “Rosatom” plans this year to begin commercial sales of micro sources with the radioactive isotope iodine-125 is required for the treatment of prostate cancer, according to the annual report of JSC “Atomenergoprom” in 2015.
«The introduction of Russian sources significantly reduces the cost of operations, as they are almost five times cheaper than imported counterparts and also have significant export potential. In 2016 is scheduled to begin commercial sales “, – quotes RIA” Novosti “reports” Atomenergoprom “.
isotope iodine-125 in the required quantities is produced in a Research Institute of Atomic Reactors (Atomic Reactors, Dimitrovgrad), microsources isotope produced at the Physics and Energy Institute named Leypunsky (FEI, Obninsk).Prostate cancer – one of the most common cancers in men. One of the most promising and effective treatment of this disease – brachytherapy. During the medical procedure maximum radiation dose delivered to the tumor without damaging the surrounding tissue and organs.
Russia’s first operation to brachytherapy using a fully Russian micro sources with iodine-125 was held in October 2015 in the Medical Radiological Research Center named Tsyba in Obninsk.
Recall April 6, the head of department of scientific and industrial base of the nuclear weapons complex of Rosatom Sergey Vlasov reported that state-owned corporation in the framework of projects on import substitution is ready to provide 70-80% of domestic equipment Russian enterprises and companies of the fuel and energy complex .
Russia has begun an extensive program of import substitution after Western sanctions have discovered the dependence of a number of important sectors of the import. President Vladimir Putin said that the sanctions have helped to clean up the Russian market, which was occupied after Russia’s accession to the WTO (2012). At the same time, Prime Minister Dmitry Medvedev said that Russia does not attempt to total replacement of all imports.
No comments:
Post a Comment